BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2018-02-23
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to evaluate the effectiveness of Tarceva®
(OSI-774, erlotinib hydrochloride) in combination with Targretin® (bexarotene) in treating
NSCLC. The safety of this treatment will also be studied, as well as the treatment's effect
on different cells in the body and the participants' overall response.